02 July 2020 Vaccibody doses first patient in Phase II clinical trial of VB10.16 in combination with immune-checkpoint inhibitor in advanced cervical cancer Vaccibody doses first patient in VB C-02 study with VB10.16 plus atezolizumab (PDF). Download Go back
